It was reported yesterday that Medicure Inc (TSXV:MPH, OTC:MCUJF), a cardiovascular pharmaceutical company, has launched its new ReDSTM PRO System of lung fluid management technology for heart failure.
The product was launched at the recent Heart Failure Society of America conference in Philadelphia, Pennysylavania. It is optimised for the point-of-care market aimed at use in hospitals and sub-acute facilities. It uses non-invasive low energy radio frequency technology that produces reliable fluid volume readings after 45 seconds of measurement.
ReDSTM PRO can be used throughout hospital facilities, from the emergency department to discharge and subacute rehabilitation.
CSL reveals top-line outcome from Phase three AEGIS-II trial of CSL112
AstraZeneca invests USD300m to expand US manufacturing for cell therapy
Innovent Biologics announces CFO transition
Cardio Diagnostics appoints Dr Vimal Ramjee as Strategic Advisor
Acticor Biotech reports positive ACTIMIS clinical study results in Lancet Neurology Journal
Sarepta Therapeutics commences Phase 3 clinical study of SRP-9003 for LGMD2E